GVK BIO Announces Successful Completion of Drug Repurposing Efforts to Identify Novel Indications
October 21, 2014 13:35 KST
HYDERABAD, INDIA--(Business Wire / Korea Newswire) October 21, 2014 -- GVK Biosciences (GVK BIO, www.gvkbio.com), Asia’s leading integrated Discovery Research and Development organization, today announced the successful completion of in-silico based alternative indications of shelved compounds for Takeda Pharmaceutical Company Limited using GVK BIO’s proprietary Drug Repurposing (http://goo.gl/qjrRlv) Platform. Taking the project to the next level, GVK BIO and Takeda have jointly agreed to evaluate the pre-clinical proof-of-concept for certain indications of selected therapeutic compounds to develop novel indications for the previously failed compounds.
Having worked for over a decade with global majors in the Pharmaceutical industry, GVK BIO has leveraged its experience and expertise in Drug Discovery and has developed a unique Drug Repurposing Platform called GRIP (http://goo.gl/LTPYSb) (GVK BIO Repurposing Integrated Platform). GRIP is a combination of proprietary Repurposing Database (http://goo.gl/6WIFQc), eight different Repurposing Algorithms (http://goo.gl/bjPt9R), Analytics tools and Visualization engine (http://goo.gl/zNnvUY).
The Repurposing database consists of over 45 databases which enable the relationship between Drug-Target-Disease. Drug repurposing algorithms allow for unbiased interpretation of the input data to predict alternative indications. GVK BIO’s value proposition in Drug Repurposing is that it offers in-silico analysis (http://goo.gl/8nthzG) as well as pre-clinical (http://goo.gl/Fzgao6) support to execute projects and establish proof of concept.
Nandu Gattu, Vice President - Drug Repurposing at GVK BIO, said, “GVK BIO is well known for its rich and extensive biological, chemical and clinical databases. A marriage between computational algorithms, analytical capabilities and our custom curated databases along with proven drug discovery experience enables us to develop a multi-pronged approach resulting in higher success rates.”
Sreeni Devidas, Vice President Business Development at GVK BIO, said, “GVK BIO has leveraged its expertise in Informatics to successfully build its Drug Repurposing Platform. The success with Takeda illustrates the value add that this approach brings to enhance the pipeline of our customers and collaborators.”
About GVK BIO
GVK Biosciences (GVK BIO) is Asia’s leading Discovery Research and Development organizations. GVK BIO provides a broad spectrum of integrated services, across the R&D and manufacturing value chain with a focus on speed and quality. GVK BIO capabilities include Discovery Research, Discovery Services, Clinical Development, Contract Manufacturing, Formulations and Informatics. GVK BIO’s 2400 employees serve a diverse and global customer base of more than 300 satisfied customers. For more information log on to www.gvkbio.com.
- GVK BIO Announces Appointment of Robert R. Ruffolo, Ph.D., to its Board of Directors
- LifeArc and GVK BIO Celebrate a Decade of Partnership, Transforming Research into Life-Saving Medicines
- GVK BIO Announces Launch of a GMP Compliant Analytical Services Laboratory
- GVK BIO Signs Definitive Agreement to Acquire Vanta Bioscience
Share this News Release